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Abstract: Objectives: The effect of amino-bisphosphonates on osteoblastic 
lineage and its potential contribution to the pathogenesis of 
bisphosphonate-associated osteonecrosis of the jaw (BONJ) remain 
controversial. We assessed the effects of zoledronic acid (ZOL) on bone 
and vascular cells of the alveolar socket using a mouse model of BONJ. 
Material and Methods: Thirty-two mice were treated twice a week with 
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molar was extracted at the third week. Alveolar sockets were assessed at 
both 3 weeks (intermediate) and 9 weeks (long-term) after molar 
extraction by semi-quantitative histomorphometry for empty lacunae, 
preosteoblasts (Osterix), osteoclasts (TRAP), and pericyte-like cells 
(CD146). Also, the bone microarchitecture was assessed by micro-CT. 
Results: Osteonecrotic-like lesions were observed in 21% of mice. 
Moreover, a decreased number of preosteoblasts contrasted with the 
increased number of osteoclasts at both time points. In addition, 
osteoclasts display multinucleation and detachment from the endosteal 
surface. Furthermore, the number of pericyte-like cells increased at the 
intermediate time point. The alveolar bone mass increased exclusively 
with long-term ZOL treatment.  
Conclusion: The severe imbalance between bone-forming cells and bone-
resorbing cells showed in this study could contribute to the pathogenesis 
of BONJ.  
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ABSTRACT  
 
Objectives: The effect of amino-bisphosphonates on osteoblastic lineage and its potential 
contribution to the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw 
(BONJ) remain controversial. We assessed the effects of zoledronic acid (ZOL) on bone and 
vascular cells of the alveolar socket using a mouse model of BONJ. 
Material and Methods: Thirty-two mice were treated twice a week with either 1ȝJkg of 
ZOL or saline for 12 weeks. The first left maxillary molar was extracted at the third week. 
Alveolar sockets were assessed at both 3 weeks (intermediate) and 9 weeks (long-term) after 
molar extraction by semi-quantitative histomorphometry for empty lacunae, preosteoblasts 
(Osterix), osteoclasts (TRAP), and pericyte-like cells (CD146). Also, the bone 
microarchitecture was assessed by micro-CT. 
Results: Osteonecrotic-like lesions were observed in 21% of mice. Moreover, a decreased 
number of preosteoblasts contrasted with the increased number of osteoclasts at both time 
points. In addition, osteoclasts display multinucleation and detachment from the endosteal 
surface. Furthermore, the number of pericyte-like cells increased at the intermediate time 
point. The alveolar bone mass increased exclusively with long-term ZOL treatment.  
Conclusion: The severe imbalance between bone-forming cells and bone-resorbing cells 
showed in this study could contribute to the pathogenesis of BONJ.  
 
KEYWORDS: Osteonecrosis of the jaw, zoledronic acid, osteoclast, osteoblast, alveolar 
bone, basic multicellular unit. 
 
 
 
 
 
 
 
  
1. Introduction 
 
Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is characterized by the 
persistent jaw bone exposure (>8 weeks) after a surgical procedure in patients with a history 
of use of bisphosphonates and without previous exposure to head and neck radiotherapy 
(Ruggiero et al. 2009). The long-term use of intravenous third-generation amino-
bisphosphonates (risedronate and zoledronic acid [ZOL]), the most powerful antiresorptive 
agents, is considered a critical risk factor related to the development of BONJ (Wessel, 
Dodson, and Zavras 2008; Basso et al. 2013). The pathogenesis of BONJ remains unknown 
and several hypothesis have been proposed; nevertheless, the suppression of bone remodeling 
induced by bisphosphonates seems to be the most consistent with their intrinsic mechanism of 
action (Mawardi et al. 2011; R. H. Kim et al. 2011; Allen and Burr 2009).  
 
Bone remodeling is the coupled process initiated by osteoclastic bone resorption 
followed by osteoblastic new bone formation (Natalie A. Sims and Martin 2014). This 
process occurs in the entire skeleton throughout life and it takes place in the basic 
multicellular units (BMUs) of cortical and trabecular bone (Natalie A. Sims and Martin 
2014). A tight control of bone remodeling in each BMU is essential for maintaining normal 
bone mass. This control is regulated by dynamic interactions between the cellular components 
and coupling factors released during bone resorption (N. A. Sims and Ng 2014). The formers 
include osteoclast precursor and mature osteoclasts, osteoblastic lineage, endothelial cells and 
pericytes, macrophages and dendritic cells (Natalie A. Sims and Martin 2014). On the other 
hand, the coupling factors are protein molecules released during the osteoclasts 
differentiation: cardiotrophin 1, sphingosine-1-phosphate (S1P), bone morphogenetic protein 
(BMP)-6 and Wnt10b, collagen triple helix repeat containing 1 (CTHRC1) and Sema4D. 
Also, the coupling factors include bone matrix proteins released during bone resorption: 
insulin growth factor (IGF)-1 and transforming growth factor (TGF)-ȕ (N. A. Sims and Ng 
2014).  
 
The clinical and preclinical benefits of blocking osteoclast differentiation and activity 
with subsequent increase of bone density using amino-bisphosphonates have been extensively 
reported (D Heymann 2010; Le Goff et al. 2010; D Heymann et al. 2005). However, their 
effects on the osteoblastic lineage remain poorly understood (Sakagami et al. 2005). Human 
biopsies show that the terminal stage of bisphosphonate-associated osteonecrotic lesions 
(bone sequestra) is characterized by the absence of the endosteal osteoblasts, empty osteocyte 
lacunae and damage in the canalicular system (Lesclous et al. 2009). These findings confirm 
the compromise of the entire osteoblastic lineage including preosteoblasts, osteoblasts, and 
osteocytes (Koch et al. 2011; Manzano-Moreno et al. 2015). On another hand, in vitro studies 
report cytotoxic effects of bisphosphonates on osteoblastic cells, decreasing their viability and 
osteogenic ability in a dose-dependent manner (Pozzi et al. 2009; Basso et al. 2013). 
Therefore, the understanding of the effect of amino-bisphosphonates on both osteoblastic 
lineage and bone remodeling in in vivo models is a crucial step to further understand the 
pathogenesis of BONJ. We postulated that osteoblastic cells are sensitive to the effect of 
amino-bisphosphonates after a surgical stimulus in alveolar bone.  The aim of this study was 
thus to assess ± at the cellular level - the intermediate and long-term effects of clinically 
relevant high doses of ZOL on the bone and vascular cell components of alveolar socket 
BMU using a surgical mouse model for BONJ. 
 
 
 
 
 
 
 
 
  
2. Material and methods 
2.1. Animals, drug administration and surgical procedure 
 Thirty-two C57BL/6 male mice (Janvier, Le Genest-Saint Isle, France) aged 10 weeks 
were randomly divided into two groups and treated intra-peritoneally (i.p.) with either 100 
ȝg/kg of ZOL (kindly provided by Novartis, Switzerland) (experimental group; n=16) or 
saline solution (control group; n=16) twice a week for 12 weeks (Supplementary appendix 1). 
The drug tolerance of the mice was assessed daily by clinical examination. The total dose of 
ZOL administered was the equivalent of a lifetime dose of the drug over 4 years of therapy in 
a 70 kg adult multiple myeloma patients (Pozzi et al. 2009). At the end of the third week, the 
first left maxillary molar was surgically extracted from all the animals (Supplementary 
appendix 1). After 6 weeks of treatment with ZOL (or saline solution), and 3 weeks after the 
molar extraction, 50 % of the animals were sacrificed to assess the situation at an intermediate 
time point (the equivalent of 2 years according to Pozzi et al., 2009). The remaining 50 % of 
the animals was sacrificed at the end of the protocol, after 12 weeks of treatment with ZOL 
(or saline solution) (the equivalent of 4 years according to Pozzi et al., 2009) and 9 weeks 
after the molar extraction, for the long-term assessment.  
 
2.2. Histology analysis 
Harvested maxillae were fixed in 4% buffered formaldehyde for 48 hours and then 
decalcified with 4.13% ethylenediaminetetraacetic acid (EDTA) and 0.2% paraformaldehyde 
in phosphate-buffered saline (PBS) for 96 hours using the KOS microwave histostation 
(Milestone, Kalamazoo, MI, USA) before embedding in paraffin. Two 4 ȝm-thick sagittal 
sections were obtained from 2 levels of the alveolar socket site (each one separated by 50 
µm). All slides were stained with Masson trichrome to assess the bone matrix and empty 
lacunae in both, bone sequestra and submucosal bone. Furthermore, all slides were stained 
with tartrate-resistant acid phosphatase (TRAP) to identify osteoclasts (Supplementary 
appendix 1). The immunostaining for osteoblastic cells was performed using rabbit 
monoclonal anti-osterix antibody (1/800; Abcam). The immunostaining of the pericytes was 
carried out using rabbit monoclonal anti-CD146 antibody (1/200; Abcam). 
 
Histological images were acquired using a NanoZoomer 2.0-RS slide scanner 
(Hamamatsu, Japan). The region of interest (ROI) corresponded to a rectangular area of 
alveolar bone comprising the full length of the alveolar socket. Static histomorphometric 
analysis of the number of empty lacunae, percentage of osteoclasts (Gobin, Battaglia, et al. 
2014a; Gobin, Huin,  et al. 2014b; Lamoureux et al. 2014), number of osterix and CD146+ 
cells in their defined ROIs, were performed using ImageJ software (NIH, Bethesda, MD, 
USA).  
 
2.3. Micro-computed tomography assessment 
The analysis of alveolar bone microarchitecture was performed at the time of necropsy 
(6 and 12 weeks) using the high-resolution X-ray micro-computed tomography (micro-CT) 
system for small-animal imaging SkyScan-1076 (SkyScan, Kontich, Belgium) 
(Supplementary appendix 1). The assessment of alveolar bone density was performed by 
measuring the mineralized bone detected within the VOI (Bone Volume; BV) and expressed 
in cubic millimeters (mm3). 
 
2.4. Statistical analysis 
All analyses were performed using GraphPad InStat Version 3.02 software (GraphPad 
Software, La Jolla, CA, USA). The histological and micro-CT results were analyzed by 
comparisons between experimental and controls groups with unpaired parametric two-tailed t-
test. Results were considered significant at p-value < 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 3. Results 
 
3.1. Zoledronic acid and molar extraction induce clinical osteonecrotic-like changes in 
alveolar bone  
A 12-week administration of high doses of ZOL was well tolerated by all mice demonstrated 
by their conservation of body weight (data not shown). In addition, 21 % of the ZOL-treated 
mice exhibited osteonecrotic-like changes, characterized by both exposed and necrotic bone 
(sequestra) in the operative site at the intermediate time point (3 weeks after molar 
extraction). The aspect of the sequestra was opaque and yellowish bone, slightly attached to 
the local mucosa (Figure 1A). Normal healing of oral mucosa was observed in mice assessed 
at the long-term time point (9 weeks after molar extraction).  
 
We next analyzed the alveolar socket by histology at two levels: bone sequestra and 
submucosal bone. All sequestrated bone displayed both the absence of osteocytes and empty 
lacunae in their whole surface (Figure 1B). On another hand, the submucosal bone exhibited 
empty lacunae exclusively in the superficial layer (Figure 1B). Their number was 
significantly higher at long-term (12 weeks) time point in the ZOL-treated group compared 
with the control (Figure 1C, p<0.01).  
 
3.2. Zoledronic acid and molar extraction decrease the number of osteoblastic cells in 
alveolar bone  
To reveal the effect of ZOL on alveolar osteoblastic cells, we performed first an histologic 
qualitative analysis followed by a semi-quantitative assessment of osterix positive cells using 
immunohistochemistry. We observed new trabecular bone in both the ZOL and saline-treated 
groups at the intermediate time point (Figure 2, upper panels). Otherwise, after long-term, the 
alveolar site exhibited a large surface of a calcified bone matrix with narrow marrow spaces 
compared with controls (Figure 2, lower panels). The osterix positive cells were detected in 
the superficial layer of the trabecular bone at both time points (Figure 2, upper and lower 
panels). Interestingly, ZOL-treated mice   significantly decreased the number of osterix 
positive cells at both intermediate (p<0.05) and long-term (p<0.01) time points. (Figure 2, 
upper and lower histograms). 
 
 
3.3. Zoledronic acid and molar extraction increase the number of aberrant giant 
multinucleated osteoclasts in alveolar bone  
Since it has been admitted that bisphosphonates, and particularly ZOL, increase the 
apoptosis of osteoclasts, thus decreasing bone remodeling, we next assessed the effect of our 
protocol on the osteoclasts in the alveolar bone. At intermediate and long-term time points, 
we observed clear changes in the morphology of TRAP+ cells between ZOL-treated mice and 
controls (Figure 3, upper and lower panels). In the former group, the shape of the osteoclasts 
was dramatically modified and the treatment resulted in the formation of large, multinucleated 
osteoclasts compared to those observed in the control group (Figure 3, upper and lower left 
panels). In addition, some of these cells were detached from the endosteal bone surface and 
located within the bone marrow spaces. Interestingly, the number of TRAP+ cells increase 
significantly in the mice that received both the intermediate (p<0.01) and long-term 
bisphosphonate treatments (p<0.05) (Figure 3, upper and lower histograms).  
 
3.4 Zoledronic acid and molar extraction increase the bone volume of the post-extraction 
alveolar socket  
Considering the high impact of ZOL on bone remodeling through its inhibition of 
osteoclastic bone resorption, we next assessed the bone mass of trabecular bone in the post-
extraction alveolar socket using a volumetric analysis by micro-tomography (micro-CT). We 
observed a significant increase in the percentage of alveolar bone volume (BV) of mice 
treated with long-term ZOL compared to controls (Figure 4, right histogram) (p<0.05). In 
contrast, no difference was observed at the intermediate time point of this protocol. 
 
3.5. Intermediate treatment with zoledronic acid and molar extraction increases the number 
of pericyte-like cells (CD146+) in alveolar bone  
Given the potentially anti-angiogenic effects of ZOL, we assessed the presence of 
CD146+ peri-vascular cells (pericytes-like) within the alveolar bone using 
immunohistochemistry. CD146+ positive cells located in the alveolar bone marrow spaces 
were clearly identified. Interestingly, a significant increase in the CD146+ pericyte-like cell 
number (p<0.05) was detected in mice treated with ZOL compared to controls at the 
intermediate time point (Supplementary appendix 2). On the contrary, no difference was 
detected in long-term ZOL-treated mice (data not shown).  
4. Discussion 
 
Maxillomandibular alveolar bone is a particular unit of the skeleton that undergoes periodic 
stimulus (e.g. facial and dental development, chewing, etc.), exhibiting a higher bone turnover 
than non-alveolar bone sites (Allen and Burr 2008). Bone turnover depends on the coupling 
activities of osteoblasts and osteoclasts in each BMUs (Natalie A. Sims and Martin 2014; N. 
A. Sims and Ng 2014). Otherwise, ZOL markedly decreases bone turnover by apoptosis of 
the osteoclasts, blocking the bone resorption and subsequently, increasing the bone mass 
(Dominique Heymann 2010). The powerful anti-resorptive effect is the main advantage for 
the treatment of human osteolytic diseases (Dominique Heymann et al. 2004; Dominique 
Heymann 2010; Le Goff et al. 2010). While the effects of bisphosphonates on bone tissue 
have been well-described in BMUs of the axial and appendicular skeleton, the specific effects 
of bisphosphonates on the maxillomandibular alveolar bone, the precise site affected by 
osteonecrosis, is still less understood. In addition, the effect of bisphosphonates on other cell 
components of BMUs such as osteoblastic, vascular and immune cells remain still 
misunderstood (N. A. Sims and Ng 2014; Pazianas 2011). We, therefore, assessed the effects 
of a human equivalent protocol of intermediate and long-term intravenous high doses of ZOL 
on bone and vascular cells involved in the bone remodeling cycle in alveolar BMUs using an 
adapted surgical mouse model of osteonecrosis of the jaw (Bi et al. 2010). 
 
We first confirmed that our protocol induced the major features of BONJ, reported in human 
series (Raje et al. 2008; Marx 2003). We showed osteonecrotic-like lesions characterized by 
the formation of sequestra and empty lacunae in the alveolar bone at the operative site. Bone 
sequestra were observed in a small number of samples at the intermediate time point of the 
treatment. Consequently, most samples showed normal healing at the operative site. The 
variable reproduction of osteonecrotic-like changes have been also reported in different 
murine models of ONJ and seems to be associated with the degree of surgical trauma (Marino 
et al. 2011). Otherwise, empty lacunae, the other key feature in human and experimental 
osteonecrotic diseases (Okazaki et al. 2009; Aghaloo et al. 2011), were recognized widely in 
the bone sequestra and selectively in the superficial layer of submucosal bone in the alveolar 
socket. Interestingly, the number of empty lacunae in the submucosal bone significantly 
increased after long-term treatment, suggesting that this finding may be associated with the 
cumulative doses fixed in the alveolar bone. This fact is in agreement with previous clinical 
and experimental reports (Ruggiero et al. 2009; Marx et al. 2005; Allen 2008; Aguirre et al. 
2012), supporting the hypothesis that long-term exposure to high doses of amino-
bisphosphonates determines their accumulation in alveolar BMUs, inducing local changes and 
constituting a potential first step in the development of osteonecrosis of the jaw (Allen 2008; 
Hoff et al. 2008; Daubiné et al. 2007; Pozzi et al. 2009).    
 
Interestingly, our study demonstrated that ZOL significantly decreased the number of 
osteoblastic cells in the alveolar BMUs. This observation was in agreement with the down-
regulation of gene expression implicated in osteoblast signalization, osteoprogenitor cell 
differentiation and activation that has been observed in patients treated with high doses of 
ZOL with and without BONJ by multiple myeloma (Raje et al. 2008). The same study 
showed that the suppression of bone formation markers was most pronounced in BONJ 
patients (Raje et al. 2008). In addition, a decrease in osteoblasts number was observed in the 
long bones after 3 weeks of systemic treatment with increasing doses of ZOL (Pozzi et al. 
2009). Moreover, the absence of woven bone in the alveolar socket after tooth extraction in 
mice treated with bisphosphonate and denosumab, two agents associated with osteonecrotic-
lesions, has recently been demonstrated (Williams et al. 2014). In this study, seric levels of 
bone-specific alkaline phosphatase, a biomarker of osteoblastic cell activity, was also 
decreased (Williams et al. 2014). Similarly, a cytotoxic effect characterized by the inhibition 
of viability, bone matrix secretion and mineralization was observed in osteoblasts after 
prolonged exposure to ZOL under in vitro conditions (Pozzi et al. 2009). While the main 
action of bisphosphonates occurs by the direct effect on osteoclasts in the bone matrix 
resorption phase of the remodeling cycle, the reduction in the number of osteoblastic cells in 
alveolar BMUs strongly suggests that ZOL has a potentially additional effect in the apposition 
phase of this cycle. Accordingly, these clinical and experimental data might be related to the 
successful use of human recombinant parathyroid hormone (rhPTH), a bone anabolic strategy, 
as a therapeutic approach for BONJ in the clinic. (Doh et al. 2015; Khan et al. 2015). 
 
Otherwise, ZOL induced an increase in the number of osteoclasts and a severe disruption in 
osteoclast morphology after both intermediate and long-term treatment. Indeed, we reported a 
significant increase in the percentage of TRAP+ cell observed in ZOL-treated mice at both 
time points and the detachment of them from the bone trabeculae surface. Taken together, 
these findings suggest a paradoxical effect of ZOL on osteoclasts, primarily supposed to 
decrease the number and activity of them. Osteoclasts with altered morphology were also 
reported in biopsies of patients under long-term of amino-bisphosphonate therapy, 
highlighting their dose-dependence (Weinstein, Roberson, and Manolagas 2009; Jobke, 
Pfeifer, and Minne 2009). The cytoskeletal reorganization of osteoclasts through inhibition of 
the protein prenylation induced by amino-bisphosphonates was proposed as an explanation 
for these facts (Jobke 2009; Roelofs et al. 2006). Similar data were observed in biopsies of 
patients after treatment with teriparatide and who had previously been treated with 
bisphosphonates (Jobke, Pfeifer, and Minne 2009). These aberrant osteoclasts may be subject 
to prolonged apoptosis or be functionally inhibited by ZOL (Weinstein, Roberson, and 
Manolagas 2009). Our study shows consistent findings to support the lack of osteoclast bone-
resorptive function in these aberrant osteoclasts. 
 
We also observed that ZOL increased the number of CD146+ pericyte-like cells 
exclusively after intermediate-term treatment. Pericytes are peri-endothelial cells that 
participate in normal tissue repair by secreting cytokines and growth factors promoting 
revascularization (Forbes and Rosenthal 2014). During aberrant tissue repair, activated 
pericytes become scar-producing myofibroblasts, which are considered a balance among 
fibrotic or full regenerative response (Forbes and Rosenthal 2014). Thus, we can hypothesize 
that the increased number of CD146+ pericyte-like cells contributed to the osteonecrotic-like 
changes observed in zoledronic acid-treated mice after a surgical injury (Bouacida et al. 
2012).  Pericytes may be increased in response to bisphosphonate in order to contribute to the 
bone remodeling. Indeed, pericytes are able to differentiate into osteoblast-like cells, 
nevertheless, pericytes show high immaturity and we can hypothesize that the differentiation 
process of pericytes towards osteoblastic lineage may be altered resulting of ONJ (Bouacida 
et al 2012). On another hand, our results are controversial considering the generic 
compromise of the vasculature in osteonecrotic diseases (e.g. femoral osteonecrosis and 
osteoradionecrosis) (H. K. W. Kim 2007; Hansen et al. 2006). Specifically, BONJ patients 
have shown vascular compromise through decreases in serum level of vascular-endothelial-
growth-factor (VEGF) (Santini et al. 2003). In addition, case report studies show an increase 
in the incidence and severity of osteonecrosis of the jaw after a single administration of 
bisphosphonates or associated with bevacizumab, a recombinant human monoclonal antibody 
that targets VEGF (Estilo et al. 2008; Lescaille et al. 2014). There are also numerous in vitro 
studies demonstrating the considerable impact of nitrogen-containing bisphosphonates over 
non nitrogen-containing bisphosphonates, decreasing the viability and migration of 
endothelial cells, as well as increasing their apoptosis (Ziebart et al. 2011; Walter et al. 2011). 
Despite this, only a restricted number of in vivo studies have shown the anti-angiogenic 
effects of nitrogen-containing bisphosphonates (Wood et al. 2002; Fournier et al. 2002; 
Stresing et al. 2011; Pabst et al. 2014). We hypothesize that our results are strongly influenced 
by the inflammatory and reparative response triggered following the molar extraction. 
 
The regulation of the bone mass is the product of the coupled phases of the bone 
remodeling cycle in each BMU: bone resorption is driven by mature osteoclasts, and 
formation is driven by pre- and mature osteoblasts. The increased alveolar bone mass at the 
long-term time point showed in our study, confirms the inactivation of osteoclasts and 
subsequent osteolysis. Interestingly, it occurs despite the decreased number of osteoblastic 
cells. We propose that the long-term treatment with ZOL affect both, the osteoclastic bone 
resorption for a long period and, transiently, the osteoblastic bone formation. Thus, a 
decreased number of osteoblastic cells were thus capable of synthesizing the bone matrix and 
increasing the alveolar bone mass. This hypothesis might be related to the reported increased 
bone turnover rate of alveolar bone rather than that of non-alveolar bone sites (Allen and Burr 
2008). Also, this finding could be explained by the bone anabolic effect of the early 
inflammatory stage in the alveolar socket after the molar extraction. The link between 
inflammation and bone repair was recently proposed and it may be regulated by oncostatin M-
signaling produced by monocyte/macrophage cells (Guihard et al. 2012). A STAT3 pathway 
activation in mesenchymal stem cells has also been reported (Nicolaidou et al. 2012).   
 
 
5. Conclusion 
 
Following administration of long-term high doses of ZOL and molar extraction in a mouse 
model of bisphosphonates-related osteonecrosis of the jaw, we confirm that the cell 
components of alveolar BMUs were significantly disrupted (Figure 5). The number of 
osteoblastic cells was dramatically reduced. In addition, the osteoclasts were inactivated, 
increased in number and exhibiting an aberrant morphology. The vascular precursors 
increased significantly after the intermediate-term treatment. Despite this evident cell 
imbalance, the alveolar bone mass increased, confirming that the effect of ZOL is mostly anti-
resorptive rather than anti-anabolic in the alveolar operative site. In short, consistent 
histological and micro-architectural findings support the disruption of the normal homeostasis 
of alveolar BMUs induced by the administration of ZOL, with an additional surgical dental 
stimulus.  
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Figure legends 
 
Figure 1: Zoledronic acid and a surgically-induced mouse model of osteonecrosis of the 
jaw (BONJ) assessed at intermediate and long-term treatment time points. (A) Clinical 
view of the sequestra after the intermediate term treatment (black arrows); (B) 0DVVRQ¶V
trichrome stained slides showing empty lacunae (black arrows) in the sequestra and 
submucosal bone of alveolar BMUs and (C) number of empty lacunae within the assessed 
area. (BMUs, basic multicellular units; w6, intermediate assessment; w12, long delay 
assessment; ZOL, zoledronic acid; NaCl, sodium chloride; ROI, region of interest; **p<0.01).  
 
 
Figure 2: Osteoblast number decreases in alveolar BMUs after zoledronic acid 
treatment and molar extraction. Immunostaining of osteoblasts (osterix+ cells) confirms 
that ZOL-treated mice show a significant decrease in the number of osteoblastic cells in 
alveolar BMUs at both time points assessed. (BMUs, basic multicellular units; week 6 (w6), 
intermediate assessment; w12, long-term assessment; ZOL, zoledronic acid; NaCl, sodium 
chloride; ROI, region of interest; *p<0.05). 
 
Figure 3: An increased number of aberrant osteoclasts were observed in alveolar BMUs 
after zoledronic acid treatment and molar extraction. TRAP-stained slices showing the 
aberrant morphology of the osteoclasts and a significant increase in the percentage of TRAP+ 
cells observed in alveolar BMUs after intermediate and long-term administration of ZOL. 
(BMUs, basic multicellular units; week 6 (w6), intermediate assessment; w12, long-term 
assessment; ZOL, zoledronic acid; NaCl, sodium chloride; *p<0.05 and **p<0.01). 
 
Figure 4: Bone volume of the extraction socket is upmodulated by bisphosphonate 
treatment and molar extraction. Volumetric assessment of the alveolar BMU shows an 
increase in the bone volume (BV) at the long-term time point. (2D, two dimensional view; 
3D, tridimensional view; 2M, second maxillary left molar; 3M, third maxillary left molar; 
BMUs, basic multicellular units; week 6, (w6) intermediate assessment; w12, long delay 
assessment; ZOL, zoledronic acid; NaCl, sodium chloride; VOI, volume of interest; *p<0.05). 
 
Figure 5: Scheme representing the disruption of cell components of alveolar BMUs induced 
by zoledronic acid. 
 
Figure legend of supplementary appendix 
 
Supplementary appendix 2: CD146+ perivascular cells are affected in alveolar BMUs by 
the intermediate zoledronic acid treatment associated with molar extraction. 
Immunodetection of CD146+ cells confirms that ZOL-treated mice show a significant 
increase in the number of perivascular cells (black arrows) in alveolar BMUs at the 
intermediate delay. (BMUs, basic multicellular units; week 6 (w6), intermediate assessment; 
w12, long delay assessment; ZOL, zoledronic acid; NaCl, sodium chloride; ROI, region of 
interest; *p<0.05). 
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Material and methods 
Ethical issues of animal housing and animal procedures  
The mice (Elevages Janvier, Le Genest Saint Isle, France) were housed in accordance 
with the institutional guidelines of the French Ethical Committee (CEEA PdL 06 ethical 
committee, authorization number: 1280.01) and the procedures were performed according to 
international ethical guidelines for animal care (authorization number: 00568.01). 
 
Surgical procedure ± molar extraction 
Under general anaesthesia (an intra-peritoneal [i.p.] solution of ketamine 100 mg/kg 
and xylazine 10 mg/kg), the mice were placed in dorsal decubitus. The molar was luxated and 
then its three roots were carefully removed using an adapted dental luxator in a previously 
decontaminated intraoral area (Betadine, France). A subcutaneous injection of Buprenorphine 
(Buprecar 0.1 mg/Kg) was performed after the surgical procedure (Palier 1 protocol). 
 
TRAP staining technique 
All slides were stained with tartrate-resistant acid phosphatase (TRAP) to identify 
osteoclasts with 1 hour of incubation in a 1 mg/mL naphthol AS-TR phosphate, 60 mmol/L 
N,Ndimethylformamide, 100 mmol/L sodium tartrate, and 1 mg/mL Fast red TR salt solution 
(Sigma Aldrich, Saint Quentin Fallavier, France) and counterstained with haematoxylin. 
 
Micro-computed tomography assessment 
All maxillae were scanned using the same parameters (pixel size 9 ȝP kV, 0.5 mm 
Al filter and 0.8 degree of rotation step). Three-dimensional reconstruction and quantification 
of bone parameters were performed in a cylindrical volume of interest (VOI) using ANT and 
CTvol software (Skyscan). 
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ABSTRACT  
Objectives: The effect of amino-bisphosphonates on osteoblastic lineage and its potential 
contribution to the pathogenesis of bisphosphonate-associated osteonecrosis of the jaw (BONJ) 
remain controversial. We assessed the effects of zoledronic acid (ZOL) on bone and vascular 
cells of the alveolar socket using a mouse model of BONJ. 
Material and Methods: Thirty-two mice were treated twice a week with either 1ȝJkg of 
ZOL or saline for 12 weeks. The first left maxillary molar was extracted at the third week. 
Alveolar sockets were assessed at both 3 weeks (intermediate) and 9 weeks (long-term) after 
molar extraction by semi-quantitative histomorphometry for empty lacunae, preosteoblasts 
(Osterix), osteoclasts (TRAP), and pericyte-like cells (CD146). Also, the bone microarchitecture 
was assessed by micro-CT. 
Results: Osteonecrotic-like lesions were observed in 21% of mice. Moreover, a decreased 
number of preosteoblasts contrasted with the increased number of osteoclasts at both time points. 
In addition, osteoclasts display multinucleation and detachment from the endosteal surface. 
Furthermore, the number of pericyte-like cells increased at the intermediate time point. The 
alveolar bone mass increased exclusively with long-term ZOL treatment.  
Conclusion: The severe imbalance between bone-forming cells and bone-resorbing cells shown 
in this study could contribute to the pathogenesis of BONJ.  
 
KEYWORDS: Osteonecrosis of the jaw, zoledronic acid, osteoclast, osteoblast, alveolar bone, 
basic multicellular unit. 
 
1. Introduction 
Bisphosphonate-associated osteonecrosis of the jaw (BONJ) is characterized by the 
persistent jaw bone exposure (>8 weeks) after a surgical procedure in patients with a history of 
use of bisphosphonates and without previous exposure to head and neck radiotherapy (Ruggiero 
et al. 2009). The long-term use of intravenous third-generation amino-bisphosphonates 
(risedronate and zoledronic acid [ZOL]), the most powerful antiresorptive agents, is considered a 
critical risk factor related to the development of BONJ (Wessel, Dodson, and Zavras 2008; Basso 
et al. 2013). The pathogenesis of BONJ remains unknown and several hypothesis have been 
proposed; nevertheless, the suppression of bone remodeling induced by bisphosphonates seems 
to be the most consistent with their intrinsic mechanism of action (Mawardi et al. 2011; R. H. 
Kim et al. 2011; Allen and Burr 2009).  
Bone remodeling is the coupled process initiated by osteoclastic bone resorption followed 
by osteoblastic new bone formation (Natalie A. Sims and Martin 2014). This process occurs in 
the entire skeleton throughout life and it takes place in the basic multicellular units (BMUs) of 
cortical and trabecular bone (Natalie A. Sims and Martin 2014). Tight control of bone 
remodeling in each BMU is essential for maintaining normal bone mass. This control is 
regulated by dynamic interactions between the cellular components and coupling factors released 
during bone resorption (N. A. Sims and Ng 2014). The former includes osteoclast precursor and 
mature osteoclasts, osteoblastic lineage, endothelial cells and pericytes, macrophages and 
dendritic cells (Natalie A. Sims and Martin 2014). On the other hand, the coupling factors are 
protein molecules released during the osteoclasts differentiation: cardiotrophin 1, sphingosine-1-
phosphate (S1P), bone morphogenetic protein (BMP)-6 and Wnt10b, collagen triple helix repeat 
containing 1 (CTHRC1) and Sema4D. Also, the coupling factors include bone matrix proteins 
released during bone resorption: insulin growth factor (IGF)-1 and transforming growth factor 
(TGF)-ȕ (N. A. Sims and Ng 2014).  
The clinical and preclinical benefits of blocking osteoclast differentiation and activity 
with subsequent increase of bone density using amino-bisphosphonates have been extensively 
reported (D Heymann 2010; Le Goff et al. 2010; D Heymann et al. 2005). However, their effects 
on the osteoblastic lineage remain poorly understood (Sakagami et al. 2005). Human biopsies 
show that the terminal stage of bisphosphonate-associated osteonecrotic lesions (bone sequestra) 
is characterized by the absence of the endosteal osteoblasts, empty osteocyte lacunae and damage 
in the canalicular system (Lesclous et al. 2009). These findings confirm the compromise of the 
entire osteoblastic lineage including preosteoblasts, osteoblasts, and osteocytes (Koch et al. 
2011; Manzano-Moreno et al. 2015). On the other hand, in vitro studies report cytotoxic effects 
of bisphosphonates on osteoblastic cells, decreasing their viability and osteogenic ability in a 
dose-dependent manner (Pozzi et al. 2009; Basso et al. 2013). Therefore, the understanding of 
the effect of amino-bisphosphonates on both osteoblastic lineage and bone remodeling in in vivo 
models is a crucial step to further understand the pathogenesis of BONJ. We postulated that 
osteoblastic cells are sensitive to the effect of amino-bisphosphonates after a surgical stimulus in 
alveolar bone. The aim of this study was thus to assess ± at the cellular level - the intermediate 
and long-term effects of clinically relevant high doses of ZOL on the bone and vascular cell 
components of alveolar socket BMU using a surgical mouse model for BONJ. 
 
2. Material and methods 
2.1. Animals, drug administration and surgical procedure 
 Thirty-two C57BL/6 male mice (Janvier, Le Genest-Saint Isle, France) aged 10 weeks 
were randomly divided into two groups and treated intra-peritoneally (i.p.) with either 100 ȝg/kg 
of ZOL (kindly provided by Novartis, Switzerland) (experimental group; n=16) or saline solution 
(control group; n=16) twice a week for 12 weeks (Supplementary appendix 1). The drug 
tolerance of the mice was assessed daily by clinical examination. The total dose of ZOL 
administered was the equivalent of a lifetime dose of the drug over 4 years of therapy in a 70 kg 
adult multiple myeloma patients (Pozzi et al. 2009). At the end of the third week, the first left 
maxillary molar was surgically extracted from all the animals (Supplementary appendix 1). After 
6 weeks of treatment with ZOL (or saline solution), and 3 weeks after the molar extraction, 50 % 
of the animals were sacrificed to assess the situation at an intermediate time point (the equivalent 
of 2 years according to Pozzi et al., 2009). The remaining 50 % of the animals was sacrificed at 
the end of the protocol, after 12 weeks of treatment with ZOL (or saline solution) (the equivalent 
of 4 years according to Pozzi et al., 2009) and 9 weeks after the molar extraction, for long-term 
assessment.  
 
2.2. Histology analysis 
Harvested maxillae were fixed in 4% buffered formaldehyde for 48 hours and then 
decalcified with 4.13% ethylenediaminetetraacetic acid (EDTA) and 0.2% paraformaldehyde in 
phosphate-buffered saline (PBS) for 96 hours using the KOS microwave histostation (Milestone, 
Kalamazoo, MI, USA) before embedding in paraffin. Two 4 ȝm-thick sagittal sections were 
obtained from 2 levels of the alveolar socket site (each one separated by 50 µm). All slides were 
stained with Masson trichrome to assess the bone matrix and empty lacunae in both, bone 
sequestra and submucosal bone. Furthermore, all slides were stained with tartrate-resistant acid 
phosphatase (TRAP) to identify osteoclasts (Supplementary appendix 1). The immunostaining 
for osteoblastic cells was performed using rabbit monoclonal anti-osterix antibody (1/800; 
Abcam). The immunostaining of the pericytes was carried out using rabbit monoclonal anti-
CD146 antibody (1/200; Abcam). 
Histological images were acquired using a NanoZoomer 2.0-RS slide scanner 
(Hamamatsu, Japan). The region of interest (ROI) corresponded to a rectangular area of alveolar 
bone comprising the full length of the alveolar socket. Static histomorphometric analysis of the 
number of empty lacunae, percentage of osteoclasts (Gobin, Battaglia, et al. 2014a; Gobin, Huin, 
et al. 2014b; Lamoureux et al. 2014), number of osterix and CD146+ cells in their defined ROIs, 
were performed using ImageJ software (NIH, Bethesda, MD, USA).  
 
2.3. Micro-computed tomography assessment 
The analysis of alveolar bone microarchitecture was performed at the time of necropsy (6 
and 12 weeks) using the high-resolution X-ray micro-computed tomography (micro-CT) system 
for small-animal imaging SkyScan-1076 (SkyScan, Kontich, Belgium) (Supplementary appendix 
1). The assessment of alveolar bone density was performed by measuring the mineralized bone 
detected within the VOI (Bone Volume; BV) and expressed in cubic millimeters (mm3). 
 
2.4. Statistical analysis 
All analyses were performed using GraphPad InStat Version 3.02 software (GraphPad 
Software, La Jolla, CA, USA). The histological and micro-CT results were analyzed by 
comparisons between experimental and controls groups with unpaired parametric two-tailed t-
test. Results were considered significant at p-value < 0.05. 
 
3. Results 
3.1. Zoledronic acid and molar extraction induce clinical osteonecrotic-like changes in alveolar 
bone  
A 12-week administration of high doses of ZOL was well tolerated by all mice demonstrated by 
their conservation of body weight (data not shown). In addition, 21 % of the ZOL-treated mice 
exhibited osteonecrotic-like changes, characterized by both exposed and necrotic bone 
(sequestra) in the operative site at the intermediate time point (3 weeks after molar extraction). 
The aspect of the sequestra was opaque and yellowish bone, slightly attached to the local mucosa 
(Figure 1A). Normal healing of oral mucosa was observed in mice assessed at the long-term time 
point (9 weeks after molar extraction).  
We next analyzed the alveolar socket by histology at two levels: bone sequestra and submucosal 
bone. All sequestrated bone displayed both the absence of osteocytes and empty lacunae in their 
whole surface (Figure 1B). On the other hand, the submucosal bone exhibited empty lacunae 
exclusively in the superficial layer (Figure 1B). Their number was significantly higher at long-
term (12 weeks) time point in the ZOL-treated group compared with the control (Figure 1C, 
p<0.01).  
 
3.2. Zoledronic acid and molar extraction decrease the number of osteoblastic cells in alveolar 
bone  
To reveal the effect of ZOL on alveolar osteoblastic cells, we performed first an histologic 
qualitative analysis followed by a semi-quantitative assessment of osterix positive cells using 
immunohistochemistry. We observed new trabecular bone in both the ZOL and saline-treated 
groups at the intermediate time point (Figure 2, upper panels). Otherwise, in the long-term, the 
alveolar site exhibited a large surface of a calcified bone matrix with narrow marrow spaces 
compared with controls (Figure 2, lower panels). The osterix positive cells were detected in the 
superficial layer of the trabecular bone at both time points (Figure 2, upper and lower panels). 
Interestingly, ZOL-treated mice significantly decreased the number of osterix positive cells at 
both intermediate (p<0.05) and long-term (p<0.01) time points. (Figure 2, upper and lower 
histograms). 
 
 
3.3. Zoledronic acid and molar extraction increase the number of aberrant giant multinucleated 
osteoclasts in alveolar bone  
Since it has been admitted that bisphosphonates, and particularly ZOL, increase the 
apoptosis of osteoclasts, thus decreasing bone remodeling, we next assessed the effect of our 
protocol on the osteoclasts in the alveolar bone. At intermediate and long-term time points, we 
observed clear changes in the morphology of TRAP+ cells between ZOL-treated mice and 
controls (Figure 3, upper and lower panels). In the former group, the shape of the osteoclasts was 
dramatically modified and the treatment resulted in the formation of large, multinucleated 
osteoclasts compared to those observed in the control group (Figure 3, upper and lower left 
panels). In addition, some of these cells were detached from the endosteal bone surface and 
located within the bone marrow spaces. Interestingly, the number of TRAP+ cells increase 
significantly in the mice that received both the intermediate (p<0.01) and long-term 
bisphosphonate treatments (p<0.05) (Figure 3, upper and lower histograms).  
 
3.4 Zoledronic acid and molar extraction increase the bone volume of the post-extraction 
alveolar socket  
Considering the high impact of ZOL on bone remodeling through its inhibition of 
osteoclastic bone resorption, we next assessed the bone mass of trabecular bone in the post-
extraction alveolar socket using a volumetric analysis by micro-tomography (micro-CT). We 
observed a significant increase in the percentage of alveolar bone volume (BV) of mice treated 
with long-term ZOL compared to controls (Figure 4, right histogram) (p<0.05). In contrast, no 
difference was observed at the intermediate time point of this protocol. 
 3.5. Intermediate treatment with zoledronic acid and molar extraction increases the number of 
pericyte-like cells (CD146+) in alveolar bone  
Given the potentially anti-angiogenic effects of ZOL, we assessed the presence of 
CD146+ peri-vascular cells (pericytes-like) within the alveolar bone using 
immunohistochemistry. CD146+ positive cells located in the alveolar bone marrow spaces were 
clearly identified. Interestingly, a significant increase in the CD146+ pericyte-like cell number 
(p<0.05) was detected in mice treated with ZOL compared to controls at the intermediate time 
point (Supplementary appendix 2). On the contrary, no difference was detected in long-term 
ZOL-treated mice (data not shown). 
 
4. Discussion 
Maxillomandibular alveolar bone is a particular unit of the skeleton that undergoes periodic 
stimulus (e.g. facial and dental development, chewing, etc.), exhibiting a higher bone turnover 
than non-alveolar bone sites (Allen and Burr 2008). Bone turnover depends on the coupling 
activities of osteoblasts and osteoclasts in each BMUs (Natalie A. Sims and Martin 2014; N. A. 
Sims and Ng 2014). Otherwise, ZOL markedly decreases bone turnover by apoptosis of the 
osteoclasts, blocking the bone resorption and subsequently, increasing the bone mass 
(Dominique Heymann 2010). The powerful anti-resorptive effect is the main advantage for the 
treatment of human osteolytic diseases (Dominique Heymann et al. 2004; Dominique Heymann 
2010; Le Goff et al. 2010). While the effects of bisphosphonates on bone tissue have been well-
described in BMUs of the axial and appendicular skeleton, the specific effects of 
bisphosphonates on the maxillomandibular alveolar bone, the precise site affected by 
osteonecrosis, is still less understood. In addition, the effect of bisphosphonates on other cell 
components of BMUs such as osteoblastic, vascular and immune cells remain still 
misunderstood (N. A. Sims and Ng 2014; Pazianas 2011). We, therefore, assessed the effects of a 
human equivalent protocol of intermediate and long-term intravenous high doses of ZOL on 
bone and vascular cells involved in the bone remodeling cycle in alveolar BMUs using an 
adapted surgical mouse model of osteonecrosis of the jaw (Bi et al. 2010). 
We first confirmed that our protocol induced the major features of BONJ, reported in human 
series (Raje et al. 2008; Marx 2003). We showed osteonecrotic-like lesions characterized by the 
formation of sequestra and empty lacunae in the alveolar bone at the operative site. Bone 
sequestra were observed in a small number of samples at the intermediate time point of the 
treatment. Consequently, most samples showed normal healing at the operative site. The variable 
reproduction of osteonecrotic-like changes have been also reported in different murine models of 
ONJ and seems to be associated with the degree of surgical trauma (Marino et al. 2011). 
Otherwise, empty lacunae, the other key feature in human and experimental osteonecrotic 
diseases (Okazaki et al. 2009; Aghaloo et al. 2011), were recognized widely in the bone 
sequestra and selectively in the superficial layer of submucosal bone in the alveolar socket. 
Interestingly, the number of empty lacunae in the submucosal bone significantly increased after 
long-term treatment, suggesting that this finding may be associated with the cumulative doses 
fixed in the alveolar bone. This fact is in agreement with previous clinical and experimental 
reports (Ruggiero et al. 2009; Marx et al. 2005; Allen 2008; Aguirre et al. 2012), supporting the 
hypothesis that long-term exposure to high doses of amino-bisphosphonates determines their 
accumulation in alveolar BMUs, inducing local changes and constituting a potential first step in 
the development of osteonecrosis of the jaw (Allen 2008; Hoff et al. 2008; Daubiné et al. 2007; 
Pozzi et al. 2009).  
Interestingly, our study demonstrated that ZOL significantly decreased the number of 
osteoblastic cells in the alveolar BMUs. This observation was in agreement with the down-
regulation of gene expression implicated in osteoblast signalization, osteoprogenitor cell 
differentiation and activation that has been observed in patients treated with high doses of ZOL 
with and without BONJ by multiple myeloma (Raje et al. 2008). The same study showed that the 
suppression of bone formation markers was most pronounced in BONJ patients (Raje et al. 
2008). In addition, a decrease in osteoblasts number was observed in the long bones after 3 
weeks of systemic treatment with increasing doses of ZOL (Pozzi et al. 2009). Moreover, the 
absence of woven bone in the alveolar socket after tooth extraction in mice treated with 
bisphosphonate and denosumab, two agents associated with osteonecrotic-lesions, has recently 
been demonstrated (Williams et al. 2014). In this study, seric levels of bone-specific alkaline 
phosphatase, a biomarker of osteoblastic cell activity, was also decreased (Williams et al. 2014). 
Similarly, a cytotoxic effect characterized by the inhibition of viability, bone matrix secretion 
and mineralization was observed in osteoblasts after prolonged exposure to ZOL under in vitro 
conditions (Pozzi et al. 2009). While the main action of bisphosphonates occurs by the direct 
effect on osteoclasts in the bone matrix resorption phase of the remodeling cycle, the reduction in 
the number of osteoblastic cells in alveolar BMUs strongly suggests that ZOL has a potentially 
additional effect in the apposition phase of this cycle. Accordingly, these clinical and 
experimental data might be related to the successful use of human recombinant parathyroid 
hormone (rhPTH), a bone anabolic strategy, as a therapeutic approach for BONJ in the clinic. 
(Doh et al. 2015; Khan et al. 2015). 
Otherwise, ZOL induced an increase in the number of osteoclasts and a severe disruption in 
osteoclast morphology after both intermediate and long-term treatment. Indeed, we reported a 
significant increase in the percentage of TRAP+ cell observed in ZOL-treated mice at both time 
points and the detachment of them from the bone trabeculae surface. Taken together, these 
findings suggest a paradoxical effect of ZOL on osteoclasts, primarily supposed to decrease the 
number and activity of them. Osteoclasts with altered morphology were also reported in biopsies 
of patients under long-term of amino-bisphosphonate therapy, highlighting their dose-
dependence (Weinstein, Roberson, and Manolagas 2009; Jobke, Pfeifer, and Minne 2009). The 
cytoskeletal reorganization of osteoclasts through inhibition of the protein prenylation induced 
by amino-bisphosphonates was proposed as an explanation for these facts (Jobke 2009; Roelofs 
et al. 2006). Similar data were observed in biopsies of patients after treatment with teriparatide 
and who had previously been treated with bisphosphonates (Jobke, Pfeifer, and Minne 2009). 
These aberrant osteoclasts may be subject to prolonged apoptosis or be functionally inhibited by 
ZOL (Weinstein, Roberson, and Manolagas 2009). Our study shows consistent findings to 
support the lack of osteoclast bone-resorptive function in these aberrant osteoclasts. 
We also observed that ZOL increased the number of CD146+ pericyte-like cells 
exclusively after intermediate-term treatment. Pericytes are peri-endothelial cells that participate 
in normal tissue repair by secreting cytokines and growth factors promoting revascularization 
(Forbes and Rosenthal 2014). During aberrant tissue repair, activated pericytes become scar-
producing myofibroblasts, which are considered a balance among fibrotic or full regenerative 
response (Forbes and Rosenthal 2014). Thus, we can hypothesize that the increased number of 
CD146+ pericyte-like cells contributed to the osteonecrotic-like changes observed in zoledronic 
acid-treated mice after a surgical injury (Bouacida et al. 2012). Pericytes may be increased in 
response to bisphosphonate in order to contribute to the bone remodeling. Indeed, pericytes are 
able to differentiate into osteoblast-like cells, nevertheless, pericytes show high immaturity and 
we can hypothesize that the differentiation process of pericytes towards osteoblastic lineage may 
be altered resulting of ONJ (Bouacida et al 2012). On the other hand, our results are 
controversial considering the generic compromise of the vasculature in osteonecrotic diseases 
(e.g. femoral osteonecrosis and osteoradionecrosis) (H. K. W. Kim 2007; Hansen et al. 2006). 
Specifically, BONJ patients have shown vascular compromise through decreases in serum level 
of vascular-endothelial-growth-factor (VEGF) (Santini et al. 2003). In addition, case report 
studies show an increase in the incidence and severity of osteonecrosis of the jaw after a single 
administration of bisphosphonates or associated with bevacizumab, a recombinant human 
monoclonal antibody that targets VEGF (Estilo et al. 2008; Lescaille et al. 2014). There are also 
numerous in vitro studies demonstrating the considerable impact of nitrogen-containing 
bisphosphonates over non nitrogen-containing bisphosphonates, decreasing the viability and 
migration of endothelial cells, as well as increasing their apoptosis (Ziebart et al. 2011; Walter et 
al. 2011). Despite this, only a restricted number of in vivo studies have shown the anti-
angiogenic effects of nitrogen-containing bisphosphonates (Wood et al. 2002; Fournier et al. 
2002; Stresing et al. 2011; Pabst et al. 2014). We hypothesize that our results are strongly 
influenced by the inflammatory and reparative response triggered following the molar extraction. 
The regulation of the bone mass is the product of the coupled phases of the bone 
remodeling cycle in each BMU: bone resorption is driven by mature osteoclasts, and formation is 
driven by pre- and mature osteoblasts. The increased alveolar bone mass at the long-term time 
point showed in our study, confirms the inactivation of osteoclasts and subsequent osteolysis. 
Interestingly, it occurs despite the decreased number of osteoblastic cells. We propose that the 
long-term treatment with ZOL affect both, the osteoclastic bone resorption for a long period and, 
transiently, the osteoblastic bone formation. Thus, a decreased number of osteoblastic cells were 
thus capable of synthesizing the bone matrix and increasing the alveolar bone mass. This 
hypothesis might be related to the reported increased bone turnover rate of alveolar bone rather 
than that of non-alveolar bone sites (Allen and Burr 2008). Also, this finding could be explained 
by the bone anabolic effect of the early inflammatory stage in the alveolar socket after the molar 
extraction. The link between inflammation and bone repair was recently proposed and it may be 
regulated by oncostatin M-signaling produced by monocyte/macrophage cells (Guihard et al. 
2012). A STAT3 pathway activation in mesenchymal stem cells has also been reported 
(Nicolaidou et al. 2012).  
 
5. Conclusion 
Following administration of long-term high doses of ZOL and molar extraction in a mouse 
model of bisphosphonates-related osteonecrosis of the jaw, we confirm that the cell components 
of alveolar BMUs were significantly disrupted (Figure 5). The number of osteoblastic cells was 
dramatically reduced. In addition, the osteoclasts were inactivated, increased in number and 
exhibiting an aberrant morphology. The vascular precursors increased significantly after the 
intermediate-term treatment. Despite this evident cell imbalance, the alveolar bone mass 
increased, confirming that the effect of ZOL is mostly anti-resorptive rather than anti-anabolic in 
the alveolar operative site. In short, consistent histological and micro-architectural findings 
support the disruption of the normal homeostasis of alveolar BMUs induced by the 
administration of ZOL, with an additional surgical dental stimulus.  
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Figure legends 
Figure 1: Zoledronic acid and a surgically-induced mouse model of osteonecrosis of the jaw 
(BONJ) assessed at intermediate and long-term treatment time points. (A) Clinical view of 
the sequestra after the intermediate term treatment (black arrows); (B) 0DVVRQ¶VWULFKURPH
stained slides showing empty lacunae (black arrows) in the sequestra and submucosal bone of 
alveolar BMUs and (C) number of empty lacunae within the assessed area. (BMUs, basic 
multicellular units; w6, intermediate assessment; w12, long delay assessment; ZOL, zoledronic 
acid; NaCl, sodium chloride; ROI, region of interest; **p<0.01).  
 
Figure 2: Osteoblast number decreases in alveolar BMUs after zoledronic acid treatment 
and molar extraction. Immunostaining of osteoblasts (osterix+ cells) confirms that ZOL-treated 
mice show a significant decrease in the number of osteoblastic cells in alveolar BMUs at both 
time points assessed. (BMUs, basic multicellular units; week 6 (w6), intermediate assessment; 
w12, long-term assessment; ZOL, zoledronic acid; NaCl, sodium chloride; ROI, region of 
interest; *p<0.05). 
 
Figure 3: An increased number of aberrant osteoclasts were observed in alveolar BMUs 
after zoledronic acid treatment and molar extraction. TRAP-stained slices showing the 
aberrant morphology of the osteoclasts and a significant increase in the percentage of TRAP+ 
cells observed in alveolar BMUs after intermediate and long-term administration of ZOL. 
(BMUs, basic multicellular units; week 6 (w6), intermediate assessment; w12, long-term 
assessment; ZOL, zoledronic acid; NaCl, sodium chloride; *p<0.05 and **p<0.01). 
 
Figure 4: Bone volume of the extraction socket is upmodulated by bisphosphonate 
treatment and molar extraction. Volumetric assessment of the alveolar BMU shows an 
increase in the bone volume (BV) at the long-term time point. (2D, two dimensional view; 3D, 
tridimensional view; 2M, second maxillary left molar; 3M, third maxillary left molar; BMUs, 
basic multicellular units; week 6, (w6) intermediate assessment; w12, long delay assessment; 
ZOL, zoledronic acid; NaCl, sodium chloride; VOI, volume of interest; *p<0.05). 
 
Figure 5: Scheme representing the disruption of cell components of alveolar BMUs induced by 
zoledronic acid. 
 
Figure legend of supplementary appendix 
Supplementary appendix 2: CD146+ perivascular cells are affected in alveolar BMUs by the 
intermediate zoledronic acid treatment associated with molar extraction. Immunodetection 
of CD146+ cells confirms that ZOL-treated mice show a significant increase in the number of 
perivascular cells (black arrows) in alveolar BMUs at the intermediate delay. (BMUs, basic 
multicellular units; week 6 (w6), intermediate assessment; w12, long delay assessment; ZOL, 
zoledronic acid; NaCl, sodium chloride; ROI, region of interest; *p<0.05). 
 
 
